Atrial natriuretic factor and liver disease
1993; Lippincott Williams & Wilkins; Volume: 17; Issue: 3 Linguagem: Inglês
10.1016/0270-9139(93)90064-t
ISSN1527-3350
Autores Tópico(s)Heart Failure Treatment and Management
ResumoHepatologyVolume 17, Issue 3 p. 500-513 Special ArticleFree Access Atrial Natriuretic Factor and Liver Disease Leonard Warner, Leonard Warner Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5S IA8Search for more papers by this authorKarl Skorecki, Karl Skorecki Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5S IA8Search for more papers by this authorLaurence M. Blendis, Laurence M. Blendis Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5S IA8Search for more papers by this authorMurray Epstein M.D., Corresponding Author Murray Epstein M.D. Nephrology Section, Veterans Affairs Medical Center, Miami, Florida 33125 Department of Medicine, University of Miami School of Medicine, Miami, Florida 33125Nephrology Section (111C1), Veterans Affairs Medical Center, 1201 N.W. 16th Street, Miami, FL 33125===Search for more papers by this author Leonard Warner, Leonard Warner Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5S IA8Search for more papers by this authorKarl Skorecki, Karl Skorecki Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5S IA8Search for more papers by this authorLaurence M. Blendis, Laurence M. Blendis Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5S IA8Search for more papers by this authorMurray Epstein M.D., Corresponding Author Murray Epstein M.D. Nephrology Section, Veterans Affairs Medical Center, Miami, Florida 33125 Department of Medicine, University of Miami School of Medicine, Miami, Florida 33125Nephrology Section (111C1), Veterans Affairs Medical Center, 1201 N.W. 16th Street, Miami, FL 33125===Search for more papers by this author First published: March 1993 https://doi.org/10.1002/hep.1840170322Citations: 37AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Epstein M. Renal sodium handling in cirrhosis. In. M Epstein, ed. The kidney in liver disease. 3rd ed. Baltimore: Williams & Wilkins, 1988: 3– 30. 2 Epstein M. The sodium retention of cirrhosis: a reappraisal. HEPATOLOGY 1986; 6: 312– 315. 3 Atlas SA, Laragh JH. Physiological actions of atrial natriuretic factor. In: PJ Mulrow, R Schrier, eds. Atrial hormones and other natriuretic factors. Bethesda, MD: American Physiological Society, 1987: 53– 76. 4 Needleman P, Adams SP, Cole BR, Currie MG, Geller DM, Michener ML, Saper CB, et al. Atriopeptin as cardiac hormones. Hypertension 1985; 7: 469– 482. 5 Cantin M, Genest J. The heart and the atrial natriuretic factor. Endocr Rev 1985; 6: 107– 127. 6 Weidmann P, Saxenhofer H, Ferrier C, Shaw SG. Atrial natriuretic peptide in man. Am J Nephrol 1988; 8: 1– 14. 7 Goetz KL. Physiology and pathophysiology of atrial peptides. Am J Physiol 1988; 254: E1– E15. 8 Atlas SA, Epstein M. Atrial natriuretic factor: implications in cirrhosis and other edematous disorders. In: M Epstein, ed. The kidney in liver disease. 3rd ed. Baltimore: Williams & Wilkins, 1988: 429– 455. 9 Better OS, Schrier RW. Disturbed volume homeostasis in patients with cirrhosis of the liver. Kidney Int 1983; 23: 303– 311. 10 Henriksen JH, Schutten HJ, Bendtsen F, Warberg J. Circulating atrial natriuretic peptide (ANP) and central blood volume (CBV) in cirrhosis. Liver 1986; 6: 361– 368. 11 Levy M. Pathophysiology of ascites formation: In: M Epstein, ed. The kidney in liver disease. 3rd ed. Baltimore: Williams & Wilkins, 1988: 209– 243. 12 deBold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89– 94. 13 Seidman CE, Duby AD, Choi E, Graham RM, Haber E, Homcy C, Smith JA, et al. The structure of rat preproatrial natriuretic factor as defined by a complementary DNA clone. Science 1986; 225: 324– 326. 14 Ballerman BJ, Zeidel ML, Gunning ME, Brenner BM. Atrial natriuretic peptide. In: Brenner and Rector, eds. The kidney. 4th ed. Philadelphia: W.B. Saunders Co., 1991; 1: 537– 558. 15 Maack T, Suzuki M, Almeida FA, Nusseenzveig D, Scarborough RM, McEnroe GA, Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675– 679. 16 Hamet P, Tremblay J, Pan SC, Skuherska R, Schiffrin EL, Garcia R, Cantin M, et al. Cyclic GMP as a mediator and biological marker of atrial natriuretic factor. J Hypertension 1986; 4 (suppl 2): S49– S56. 17 Sonnenberg H. Mechanisms of release and renal tubular actions of atrial natriuretic factor. Fed Proc 1986; 45: 2106– 2110. 18 Huang CL, Lewicki J, Johnson LK, Cogan MG. Renal mechanisms of action of rat atrial natriuretic factor. J Clin Invest 1985; 75: 769– 773. 19 Dillingham MH, Anderson RJ. Inhibition of vasopressin action by atrial natriuretic factor. Science 1986; 231: 1572– 1573. 20 Maack T, Marion DN, Camargo MJ, Kleinert HD, Laragh JH, Vaughan ED Jr, Atlas SA. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function and the reninaldosterone system in dogs. Am J Med 1984; 77: 1069– 1075. 21 Bussien JP, Biollaz J, Waeber B, Nussberger J, Turini GA, Brunner HR, Brunner-Ferber F, et al. Dose dependent effect of atrial natriuretic peptide on blood pressure, heart rate and skin blood flow of normal volunteers. J Cardiovasc Pharmacol 1986; 8: 216– 220. 22 Kleinert HD, Maack T, Atlas SA, Januszewicz A, Sealey JE, Laragh JH. Atrial natriuretic factor inhibits angiotensin-norepinephrine-, and potassium-induced vascular contractility. Hypertension 1984; 6 (suppl I): 1143– 1147. 23 Samson WK. Atrial natriuretic factor inhibits dehydration and hemorrhage-induced vasopressin release. Neuroendocrinology 1985; 40: 277– 279. 24 Epstein M. Atrial natriuretic factor in patients with liver disease. Am J Nephrol 1989; 9: 89– 100. 25 Bonkovsky HL, Hartle DK, Mellen BG, Kutner M, Galambos JT. Plasma concentrations of immunoreactive atrial natriuretic peptide in hospitalized cirrhotic and non-cirrhotic patients: Evidence of a role of deficient atrial natriuretic peptide in pathogenesis of cirrhotic ascites. Am J Gastroenterol 1988; 83: 531– 535. 26 Burghardt W, Wernze H, Diehl KL. Atrial natriuretic peptide in cirrhosis: Relation to stage of disease, sympathoadrenal system and renin-aldosterone axis. Klin Wochenschr 1986; 64 (suppl 6): 103– 107. 27 Vinel JP, Denoyel PH, Chabrier PE, Viossat I, Cales P, Caucanas JP, Braquet P, et al. Relationships between atrial natriuretic factor, plasma renin activity and plasma volume in cirrhotic patients with and without ascites. In: BM Brenner, JH Laragh, eds. Advances in atrial peptide research. New York: Raven Press, 1988: 416– 421. 28 Epstein M, Loutzenhiser R, Norsk P, Atlas S. Relationship between plasma ANF responsiveness and renal sodium handling in cirrhotic humans. Am J Nephrol 1989; 9: 133– 143. 29 Campbell PJ, Skorecki KL, Logan AG, Wong PY, Leung WM, Greig P, Blendis LM. Acute effects of peritoneovenous shunting on plasma atrial natriuretic peptide in cirrhotic patients with massive refractory ascites. Am J Med 1988; 84: 112– 119. 30 Burghardt W, Muller R, Diehl KL, Wernze H. Interrelationship between atrial natriuretic peptide and plasma renin, aldosterone and catecholamines in hepatic cirrhosis: the effect of passive leg rising. S. Kardiol 1988; 77 (suppl 2): 104– 110. 31 Epstein M, Preston R, Aceto R, Camargo MJK, Loutzenhiser R, Atlas S. Dissociation of plasma irANF and renal sodium handling in cirrhotic humans undergoing water immersion [Abstract]. Kidney Int 1987; 31: 269. 32 Morgan TR, Imada T, Hollister AS, Inagami T. Plasma human atrial natriuretic factor in cirrhosis and ascites with and without functional renal failure. Gastroenterology 1988; 95: 1641– 1647. 33 Skorecki KL, Leung WM, Campbell P, Warner LC, Wong PY, Bull S, Logan AG, et al. Role of atrial natriuretic peptide in the natriuretic response to central volume expansion induced by head-out water immersion in sodium retaining cirrhotic subjects. Am J Med 1988; 85: 375– 382. 34 Ginès P, Jimenez W, Arroyo V, Navasa M, Lopez C, Tito L, Serra A, et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. HEPATOLOGY 1988; 8: 636– 642. 35 Warner LC, Campbell PJ, Morali G, Logan AG, Skorecki KL, Blendis LM. The response of atrial natriuretic factor (ANF) and sodium excretion to dietary sodium challenges in patients with chronic liver disease. HEPATOLOGY 1990; 12: 460– 466. 36 Sonnenberg H, Veress AT. Cellular mechanism of release of atrial natriuretic factor. Biochem Biophys Res Commun 1984; 124: 443– 449. 37 Sonnenberg H, Krebs RF, Veress AT. Release of atrial natriuretic factor from incubated rat heart atria. IRCS Med Sci 1984; 12: 783– 784. 38 Manning PT, Schwartz D, Katsube NC, Holmberg SW, Needleman P. Vasopressin-stimulated release of atriopeptin: endocrine antagonists in fluid homeostasis. Science 1985; 229: 395– 397. 39 Sanfield JA, Shenker Y, Grekin RJ, Rosen SG. Epinephrine increases plasma immunoreactive atrial natriuretic hormone levels in humans. Am J Physiol 1987; 252: E740– E745. 40 Rankin AJ. Mechanisms for the release of atrial natriuretic peptide. Can J Physiol Pharmacol 1987; 65: 1673– 1679. 41 Campbell PJ, Leung WM, Logan A, Debowski TE, Blendis LM, Skorecki KL. Hyperresponsiveness to water immersion in sodium retaining cirrhotics: the role of atrial natriuretic peptide. Clin Invest Med 1988; 11: 392– 395. 42 Wilkinson SP, Arroyo VA, Moodie H, Blendis LM, Williams R. Abnormalities, of sodium excretion and other disorders of renal function in fulminant hepatic failure. Gut 1976; 17: 501– 505. 43 Guarner F, Hughes RD, Gimson AES, Williams R. Renal function in fulminant hepatic failure: haemodynamics and renal prostaglandins. Gut 1987; 28: 1643– 1647. 44 Panos MZ, Anderson JV, Forbes A, Payne N, Slater JDH, Rees L, Williams R. Human atrial natriuretic factor and reninaldosterone in paracetamol induced fulminant hepatic failure. Gut 1991; 32: 85– 89. 45 Tikkanen I, Fyhrquist F, Metsärinne K, Leidenius R. Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. Lancet 1985; 2: 66– 69. 46 Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. Metabolic clearance rate and plasma half life of alpha-human natriuretic peptide in man. Life Sci 1986; 38: 1827– 1833. 47 Henriksen JH, Bulöw JB, Tronier B. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metabolism 1987; 26: 463– 468. 48 Holst-Pedersen J, Andersen H, Olsen SP, Henriksen JH. Pharmacokinetics and metabolism of neurotensin in man. J Clin Endocrinol Metab 1989; 68: 294– 300. 49 Henriksen JH, Staun-Olsen P, Mogensen NB, Fahrenkrug J. Circulating endogenous vasoactive intestinal polypeptide (VIP) in patients with uraemia and liver cirrhosis. Eur J Clin Invest 1986; 16: 211– 216. 50 Hollister AS, Rodeheffer RJ, White FJ, Potts JR, Imada T, Inagami T. Clearance of atrial natriuretic factor by lung, liver and kidney in human subjects and the dog. J Clin Invest 1989; 83: 623– 628. 51 Henriksen JH, Bendtsen F, Schütten HJ, Warberg J. Hepaticintestinal disposal of endogenous human alpha natriuretic factor 99–126 (ANF) in patients with cirrhosis. Am J Gastroenterol 1990; 85: 1155– 1159. 52 Vierhapper H, Gasic S, Nowotny P, Waldhaüsl W. Splanchnic disposal of human natriuretic peptide in humans. Metabolism 1988; 37: 973– 975. 53 Henriksen JH, Bendtsen F, Gerbes AL. Splanchnic removal of atrial natriuretic factor (ANF) in man: Enhancement after food intake. Metabolism 1990; 39: 553– 556. 54 Arendt RM, Gerbes AL, Ritter D, Stangl E, Bach P, Zahringer J. Atrial natriuretic factor in plasma of patients with arterial hypertension, heart failure, or cirrhosis of the liver. J Hypertension 1986; 4 (suppl 2): S131– S135. 55 Epstein M, Loutzenhiser R, Friedland E, Aceto RM, Camargo MJF, Atlas SA. Increases in circulating atrial natriuretic factor during immersion induced central hypervolemia in normal humans. J Hypertension 1986; 4 (suppl 2): S93– S99. 56 Epstein M. Renal effects of head-out water immersion in man: implications for an understanding of volume homeostasis. Physiol Rev 1978; 58: 529– 581. 57 Epstein M. Renal effects of head-out water immersion in humans: a 15 year update. Physiol Rev 1992; 72: 563– 621. 58 Epstein M, Loutzenhiser R. Effects of water immersion on ANP release in humans. Am J Nephrol 1989; 9: 1– 24. 59 Epstein M, Loutzenhiser R, Friedland E, Aceto RM, Camargo MJF, Atlas SA. Relationship of increased plasma atrial natriuretic factor and renal sodium handling during immersion induced central hypervolemia in normal humans. J Clin Invest 1987; 76: 1705– 1709. 60 Warner LC, Morali GA, Miller JA, Logan AG, Skorecki KL, Blendis LM. Aldosterone, atrial natriuretic factor and sodium intake as determinants of the natriuretic response to head-out water immersion in healthy subjects. Clin Sci 1991; 80: 475– 480. 61 Leung WH, Logan AG, Campbell PJ, Debowski TE, Bull SB, Wong PY, Blendis LM, et al. Role of atrial natriuretic peptide and urinary cGMP in the natriuretic and diuretic response to central hypervolemia in normal human subjects. Can J Physiol Pharmacol 1987; 65: 2076– 2080. 62 Gerzer R, Witzgall H, Tremblay J, Gutkowska J, Hamet P. Rapid increase in plasma and urine cGMP after bolus injection of atrial natriuretic factor in man. J Clin Endocrinol Metab 1985; 61: 1217– 1219. 63 Tremblay J, Gerzer R, Vinay P, Pang SC, Beliveau R, Hamet P. The increase of cGMP by atrial natriuretic factor correlates with the distribution of particulate guanylate cyclase. FEBS Lett 1985; 181: 17– 22. 64 Nicholls KM, Shapiro MD, Kluge R, Chung HM, Bichet DG, Schrier RW. Sodium excretion in advanced cirrhosis: effect of expansion of central blood volume and suppression of plasma aldosterone. HEPATOLOGY 1986; 6: 235– 238. 65 Tesar V, Horky K, Petryl J, Kozakova M, Gregorova I, Brodanova N, Kordac V, et al. Atrial natriuretic factor in liver cirrhosis: the influence of volume expansion. Horm Metab Res 1989; 21: 519– 522. 66 Reznick RK, Langer B, Taylor BR, Seif S, Blendis LM. Hyponatremia and arginine vasopressin secretion in patients with refractory hepatic ascites undergoing peritoneovenous shunting. Gastroenterology 1983; 84: 713– 718. 67 Klepetko W, Muller CH, Hartter E, Miholics J, Schwartz CH, Woloszczuk W, Moeschl P. Plasma atrial natriuretic factor in cirrhotic patients with ascites: effect of peritoneovenous shunt implantation. Gastroenterology 1988; 95: 764– 770. 68 Salerno F, Badalamenti S, Maser P, Lorenzano E, Incerti P, Dioguardi N. Atrial natriuretic factor in cirrhotic patients with tense ascites: effect of large-volume paracentesis. Gastroenterology 1990; 98: 1063– 1070. 69 Salerno F, Badalamenti S, Incerti P, Capozza L, Mainardi L. Renal response to atrial natriuretic peptide in patients with advanced liver cirrhosis. HEPATOLOGY 1988; 8: 21– 26. 70 Fried T, Aronoff GR, Benabe JE, Brunner HR, DiBona GF, Fleischhauer T, Lam M, et al. Renal and hemodynamic effects of atrial natriuretic peptide in patients with cirrhosis. Am J Med Sci 1990; 299: 2– 9. 71 Petrillo A, Scherrer JJG, Nussberger J, Marder H, deVane P, Waeber B, Hofstetter JR, et al. Atrial natriuretic peptide administered as intravenous infusion or bolus injection to patients with liver cirrhosis and ascites. J Cardiovasc Pharmacol 1988; 12: 279– 285. 72 Badalamenti S, Borroni G, Lorenzano E, Incerti P, Salerno F. Renal effects in cirrhotic patients with avid sodium retention of ANF injection during norepinephrine infusion. HEPATOLOGY 1992; 15: 824– 829. 73 Ginès P, Tito L, Arroyo V, Llach J, Salmeron JM, Ginès A, Jimenez W, et al. Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Gastroenterology 1992; 102: 280– 286. 74 Beutler JJ, Koomens HA, Rabelink TJ, Gaillard CA, VanHattum J, Boer P, Mees EJD. Blunted natriuretic response and low blood pressure after atrial natriuretic factor in early cirrhosis. HEPATOLOGY 1989; 10: 148– 153. 75 Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodès J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988; 8: 1151– 1157. 76 Laffi G, Marra F, Pinzani M, Meacci E, Tosti-Guerra C, DeFeo ML, Gentilini P. Effects of repeated atrial natriuretic peptide bolus injections in cirrhotic patients with refractory ascites. Liver 1989; 9: 315– 321. 77 Laffi G, Pinzani M, Meacci E, LaVilla G, Renzi D, Baldi E, Cominelli F, et al. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. Gastroenterology 1989; 96: 167– 177. 78 Wesson LG. Electrolyte excretion in relation to diurnal cycles of renal function. Medicine 1964; 43: 547– 592. 79 Moore-Ede MC, Herd J. Renal electrolyte circadian rhythms: independence from feeding and activity patterns. Am J Physiol 1977; 232: F128– F135. 80 Goldman R. Studies in diurnal variation of water and electrolyte excretion: nocturnal diuresis of water and sodium in congestive cardiac failure and cirrhosis of the liver. J Clin Invest 1951; 30: 1191– 1199. 81 Papper S, Rosenbaum JD. Abnormalities in the excretion of water and sodium in "compensated" cirrhosis of the liver. J Lab Clin Med 1952; 40: 523– 530. 82 Bernardi M, de Palma R, Trevisani F, Santini C, Capani F, Baraldini M, Gasbarrini G. Chronobiological study of factors affecting plasma aldosterone concentration in cirrhosis. Gastroenterology 1986; 91: 683– 691. 83 Bernardi M, Trevisani F, de Palma R, Ligabue A, Capani F, Baraldini M, Gasbarrini C. Chronobiological evaluation of sympathoadrenergic function in cirrhosis. Gastroenterology 1987; 93: 1178– 1186. 84 Colantonio D, Pasqualetti P, Casale R, Desiati P. Giandomenico G, Natali G. Atrial natriuretic peptide-renin-aldoaterone system in cirrhosis of the liver: circadian study. Life Sci 1989; 45: 631– 635. 85 Panos MZ, Anderson JV, Payne N, Langley P, Slater JDH, Rees L, Williams R. Plasma atrial natriuretic peptide and reninaldosterone in patients with cirrhosis and ascites basal levels, changes during daily activity and nocturnal diuresis. HEPATOLOGY 1992; 16: 82– 87. 86 Gerbes AL, Wernze H, Arendt RM, Reidel A, Sauerbruch T, Paumgartner G. Atrial natriuretic factor and renin-aldosterone in volume regulation in patients with cirrhosis. HEPATOLOGY 1989; 9: 417– 422. 87 Koepke JP, DiBona GF. Blunted natriuresis to atrial natriuretic peptide in chronic sodium retaining disorders. Am J Physiol 1987; 252: F865– F871. 88 Koepke JP, Jones S, DiBona GF. Renal nerves mediate blunted natriuresis to atrial natriuretic peptide in cirrhotic rats. Am J Physiol 1987; 252: R1019– R1023. 89 Morgan DA, Peuler JD, Koepke JP, Mark AL, DiBona GF. Renal sympathetic nerves attenuate the natriuretic effects of atrial peptide. J Lab Clin Med 1989; 114: 538– 544. 90 Nicholls KM, Shapiro MD, Van Putten VJ, Kluge R, Chung HM, Bichet DG, Schrier RW. Elevated plasma norepinephrine concentrations in decompensated cirrhosis: association with increased secretion rates, normal clearance rates, and suppressibility by central blood expansion. Circ Res 1985; 56: 457– 461. 91 Solis-Herruzo JA, Duran A, Favela V, Castellano G, Madrid JL, Munoz-Yague MR, Morillas JD, et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 1987; 5: 167– 173. 92 Morali G, Floras JS, Legault L, Tobe S, Skorecki KL, Blendis LM. Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. Am J Med 1991; 91: 383– 392. 93 Moe GW, Legault L, Skorecki KL. Control of extracellular fluid volume and pathophysiology of edema formation. In: BM Brenner, JF Rector, eds. The kidney. 4th ed. Philadelphia W.B. Saunders Co, 1991: 623– 676. 94 Sonnenberg H, Cupples WA, deBold AJ, Veress AT. Intrarenal localization of the effect of cardiac atrial extract. Can J Physiol Pharmacol 1982; 60: 1149– 1152. 95 Baum M, Toto RD. Lack of a direct effect of atrial natriuretic factor in the rabbit proximal tubule. Am J Physiol 1986; 250: F66– F69. 96 Sonnenberg H, Honrath U, Chung CK, Wilson DR. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol 1986; 250: F963– F966. 97 Liu FY, Cogan MG. Atrial natriuretic factor does not inhibit basal or angiotensin II stimulated proximal transport. Am J Physiol 1988; 255: F434– F437. 98 Ziedel ML, Kikeri D, Silva P, Burrows M, Brenner BM. Atrial natriuretic peptides inhibit conductive sodium uptake by rabbit inner medullary collecting duct cells. J Clin Invest 1988; 82: 1067– 1074. 99 Morali GA, Tobe S, Skorecki KL, Blendis LM. Refractory ascites: modulation of ANF unresponsiveness by mannitol HEPATOLOGY 1992; 16: 42– 48. 100 Kremer S, Troyer D, Kreisberg J, Skorecki KL. Interaction of atrial natriuretic peptide stimulated guanylate cyclase and vasopressin-stimulated calcium signaling pathways in glomerular mesangial cells. Arch Biochem Biophys 1988; 269: 763– 770. 101 Jaiswal RK, Jaiswal N, Sharma RK. Negative regulation of atrial natriuretic factor receptor coupled membrane guanylate cyclase by phorbol ester. FEBS Lett 1988; 227: 47– 50. 102 Nambi P, Whitman M, Gessner G, Aiyar N, Crooke ST. Vasopressin-mediated inhibition of atrial natriuretic factor stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci USA 1986; 83: 8492– 8495. 103 Smith JB, Lincoln TM. Angiotensin decreases cGMP accumulation produced by atrial natriuretic factor. Am J Physiol 1987; 253: C147– C150. 104 Gee NS, Bowes MA, Buck P, Kenny AJ. An immunoradiometric assay for endopeptidase-24.11 shows it to be widely distributed enzyme in pig tissues. Biochem J 1985; 228: 119– 126. 105 Trapani AJ, Smits GJ, McGraw DE, Spear KL, Koepke JP, Olins GM, Blaine EH. Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide. J Cardiovasc Pharmacol 1989; 14: 419– 424. 106 Wilkins MR, Settle SL, Stockmann PT, Needleman P. Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc Natl Acad Sci USA 1990; 87: 6465– 6469. 107 Legault L, Cernacek P, Levy M. Attempts to alter the heterogenous response to ANP in sodium retaining caval dogs. Can J Physiol Pharmacol 1992; 70: 897– 904. 108 Smits GJ, McGraw DE, Trapani AJ. Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects. Am J Physiol 1990; 258: F1417– F1424. 109 Sybertz EJ Jr, Chiu PJS, Watkins RW, Vemulopalli S. Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action. Can J Physiol Pharmacol 1991; 69: 1628– 1635. 110 Schultz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssman WG. Isolation and structural analysis of "urodilatin," a new peptide of the cardiodilatin-(ANP) family, extracted from human urine. Klin Wochenschr 1988; 66: 752– 759. 111 Goetz KL. Renal natriuretic peptide (urodilatin?) and atriopeptin: evolving concepts. Am J Physiol 1991; 261: F921– F932. 112 Drummer C, Fiedler F, Konig A, Gerzer R. Urodilatin, a kidney-derived natriuretic factor, is excreted with a circadian rhythm and is stimulated by saline infusion in man. J Am Soc Nephrol 1991; 1: 1109– 1113. 113 Kenny AJ, Stephenson SL. Role of endopeptidase 24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett 1988; 232: 1– 8. 114 Levy M. Sodium retention and ascites formation in dogs with experimental portal cirrhosis. Am J Physiol 1977; 237: F572– F585. 115 Levy M, Allotey JB. Temporal relationships between urinary salt retention and altered systemic hemodynamics in dogs with experimental cirrhosis. J Lab Clin Med 1978; 92: 560– 569. 116 Almeida FA, Muneya M, Maack T. Atrial natriuretic factor increases hematocrit and decreases plasma volume in nephrectomized rats. Life Sci 1986; 38: 1193– 1199. 117 Huxley VH, Tucker VL, Verburg KM, Freeman RH. Increased capillary hydraulic conductivity induced by atrial natriuretic peptide. Circ Res 1987; 60: 304– 307. 118 Jonas GM, Morgan TR, Morgan K, Thillainadarajah I, Hornacek C. Atrial natriuretic peptide in portal vein-ligated rats: alterations in cardiac production, plasma level and glomerular receptor density and affinity. HEPATOLOGY 1992; 15: 696– 701. Citing Literature Volume17, Issue3March 1993Pages 500-513 ReferencesRelatedInformation
Referência(s)